Measures of Thrombosis and Fibrinolysis

Clinics in Laboratory Medicine

Volumn 26, Issue 3, 2006, Pages 655-678

  Choi, Brian G ^a   Vilahur, Gemma ^a   Ibanez, Borja ^a   Zafar, M Urooj ^a   Rodriguez, Jose ^a   Badimon, Juan J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CITRATE SODIUM; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE; EDETIC ACID; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FIBRINOPEPTIDE A; HEPARIN; PHOSPHOLIPID ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; ATHEROGENESIS; BLOOD CHEMISTRY; BLOOD CLOTTING TEST; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIRCADIAN RHYTHM; CLINICAL PRACTICE; DISEASE MARKER; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; HEMOSTASIS; HIGH RISK PATIENT; HISTORY OF MEDICINE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PHLEBOTOMY; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; RADIOIMMUNOASSAY; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; RISK REDUCTION; STANDARDIZATION; TEMPERATURE SENSITIVITY; THROMBOSIS;

BIOLOGICAL MARKERS; FIBRINOLYSIS; HUMANS; REFERENCE STANDARDS; SPECIMEN HANDLING; THROMBOSIS;

EID: 33747822615     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2006.06.002     Document Type: Review

References (93)

1. Fuster V., Moreno P.R., Fayad Z.A., et al. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 46 6 (2005) 937-954
2. Fuster V., Fayad Z.A., and Badimon J.J. Acute coronary syndromes: biology. Lancet 353 Suppl 2 (1999) SII5-SII9
3. Lubitz S.A. Early reactions to Harvey's circulation theory: the impact on medicine. Mt Sinai J Med 71 4 (2004) 274-280
4. Donne A. Origin of blood corpuscles formation and their destruction. C R Acad Sci (Paris) 14 (1842) 366-368 [in French]
5. Virchow R. Thrombosis and Embolism. Vasculitis and septic infection. In: Collections of manuscripts of scientific medicine. Frankfurt: a.M., Meidinger, Sohn u. Co.; 1856. p. 219-732 [in German].
6. Hustin A. Principles of a new method for blood transfusion. J Méd Brux 12 (1914) 436-439 [in French]
7. Murphy S., and Gardner F.H. Effects of storage temperature on maintenance of platelet viability-deleterious effect of refridgerated storage. New Engl J Med 280 (1969) 1094-1098
8. Danesh J., Whincup P., Walker M., et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 321 7255 (2000) 199-204
9. Danesh J., Collins R., Peto R., et al. Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J 21 7 (2000) 515-520
10. Danesh J., Whincup P., Walker M., et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 103 19 (2001) 2323-2327
11. Whincup P.H., Danesh J., Walker M., et al. von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 23 22 (2002) 1764-1770
12. Rumley A., Lowe G.D., Sweetnam P.M., et al. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. Br J Haematol 105 1 (1999) 110-116
13. Lowe G.D., Yarnell J.W., Sweetnam P.M., et al. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 79 1 (1998) 129-133
14. Haines A.P., Howarth D., North W.R., et al. Haemostatic variables and the outcome of myocardial infarction. Thromb Haemost 50 4 (1983) 800-803
15. Lagrand W.K., Visser C.A., Hermens W.T., et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?. Circulation 100 1 (1999) 96-102
16. Lowe G.D.O. Blood rheology, haemostasis and vascular disease. In: Bloom A.L., Forbes C.D., and Thomas D.P. (Eds). Haemostasis and thrombosis. 3rd edition (1994), Churchill Livingstone, Edinburgh (UK) 1169-1188
17. Reiner A.P., Siscovick D.S., and Rosendaal F.R. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost 85 4 (2001) 584-595
18. Lammers M. Dilution of citrated plasma. Eur J Clin Chem Clin Biochem 34 4 (1996) 369
19. Duncan E.M., Casey C.R., Duncan B.M., et al. Effect of concentration of trisodium citrate anticoagulant on calculation of the international normalised ratio and the international sensitivity index of thromboplastin. Thromb Haemost 72 1 (1994) 84-88
20. Engelberts I., Moller A., Schoen G.J., et al. Evaluation of measurement of human TNF in plasma by ELISA. Lymphokine Cytokine Res 10 1-2 (1991) 69-76
21. Willems H.P., den Heijer M., Lindemans J., et al. Measurement of total homocysteine concentrations in acidic citrate- and EDTA-containing tubes by different methods. Clin Chem 50 10 (2004) 1881-1883
22. Blann A.D., Lip G.Y., Beevers D.G., et al. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemost 77 6 (1997) 1077-1080
23. Graham J., and Caine A.D.B. Soluble P-selectin should be measured in citrated plasma, not in serum. Br J Haematol 121 (2003) 530-532
24. Malik I., Danesh J., Whincup P., et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 358 9286 (2001) 971-976
25. Ridker P.M., Buring J.E., and Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 103 4 (2001) 491-495
26. Hillis G.S., Terregino C., Taggart P., et al. Elevated soluble P-selectin levels are associated with an increased risk of early adverse events in patients with presumed myocardial ischemia. Am Heart J 143 2 (2002) 235-241
27. Mackie I.J., Kitchen S., Machin S.J., et al. Guidelines on fibrinogen assays. Br J Haematol 121 3 (2003) 396-404
28. Boyanton Jr. B.L., and Blick K.E. Stability studies of twenty-four analytes in human plasma and serum. Clin Chem 48 12 (2002) 2242-2247
29. Thom J., Gilmore G., Yi Q., et al. Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma. J Thromb Haemost 2 11 (2004) 2067-2069
30. Daan S.A.J. Circadian contribution to survival. In: Aschoff J., Daan S., and Groos G. (Eds). Vertebrate circadian system (1982), Springer-Verlag, Berlin 305-321
31. Muller J.E., Tofler G.H., and Stone P.H. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 79 4 (1989) 733-743
32. Muller J.E., Stone P.H., Turi Z.G., et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 313 21 (1985) 1315-1322
33. Marler J.R., Price T.R., Clark G.L., et al. Morning increase in onset of ischemic stroke. Stroke 20 4 (1989) 473-476
34. Casetta I., Granieri E., Portaluppi F., et al. Circadian variability in hemorrhagic stroke. JAMA 287 10 (2002) 1266-1267
35. Kapiotis S., Jilma B., Quehenberger P., et al. Morning hypercoagulability and hypofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1 + 2, and plasmin-plasmin inhibitor complex. Circulation 96 1 (1997) 19-21
36. Pinotti M., Bertolucci C., Portaluppi F., et al. Daily and circadian rhythms of tissue factor pathway inhibitor and factor VII activity. Arterioscler Thromb Vasc Biol 25 3 (2005) 646-649
37. Iversen P.O., Groot P.D., Hjeltnes N., et al. Impaired circadian variations of haemostatic and fibrinolytic parameters in tetraplegia. Br J Haematol 119 4 (2002) 1011-1016
38. Undar L., Ertugrul C., Altunbas H., et al. Circadian variations in natural coagulation inhibitors protein C, protein S and antithrombin in healthy men: a possible association with interleukin-6. Thromb Haemost 81 4 (1999) 571-575
39. Angleton P., Chandler W.L., and Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 79 1 (1989) 101-106
40. Miller G.J., Stirling Y., Howarth D.J., et al. Dietary fat intake and plasma factor VII antigen concentration. Thromb Haemost 73 5 (1995) 893
41. Cigolini M., Targher G., Seidell J.C., et al. Plasma factor VII and its relation to adipose tissue fatty acids and other atherogenic risk factors in healthy men. Eur J Clin Invest 26 3 (1996) 247-253
42. Miller G.J. Effects of diet composition on coagulation pathways. Am J Clin Nutr 67 3 Suppl (1998) 542S-545S
43. Kjalke M., Silveira A., Hamsten A., et al. Plasma lipoproteins enhance tissue factor-independent factor VII activation. Arterioscler Thromb Vasc Biol 20 7 (2000) 1835-1841
44. Colditz G.A. The Nurses' Health Study: a cohort of US women followed since 1976. J Am Med Womens Assoc 50 2 (1995) 40-44
45. Michaud D.S., Spiegelman D., Clinton S.K., et al. Fluid intake and the risk of bladder cancer in men. N Engl J Med 340 18 (1999) 1390-1397
46. Nilsson L., Hedner U., Nilsson I.M., et al. Shelf-life of bank blood and stored plasma with special reference to coagulation factors. Transfusion 23 5 (1983) 377-381
47. Heil W., Grunewald R., Amend M., et al. Influence of time and temperature on coagulation analytes in stored plasma. Clin Chem Lab Med 36 7 (1998) 459-462
48. Pai J.K., Curhan G.C., Cannuscio C.C., et al. Stability of novel plasma markers associated with cardiovascular disease: processing within 36 hours of specimen collection. Clin Chem 48 10 (2002) 1781-1784
49. Mondoro T.H., Shafer B.C., and Vostal J.G. Restoration of in vitro responses in platelets stored in plasma. Am J Clin Pathol 111 5 (1999) 693-699
50. Lozano M., Estebanell E., Cid J., et al. Platelet concentrates prepared and stored under currently optimal conditions: minor impact on platelet adhesive and cohesive functions after storage. Transfusion 39 9 (1999) 951-959
51. Papp A.C., Hatzakis H., Bracey A., et al. ARIC hemostasis study-I. Development of a blood collection and processing system suitable for multicenter hemostatic studies. Thromb Haemost 61 1 (1989) 15-19
52. Winn D.M., Reichman M.E., and Gunter E. Epidemiologic issues in the design and use of biologic specimen banks. Epidemiol Rev 12 (1990) 56-70
53. Cushman M., Cornell E.S., Howard P.R., et al. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 41 2 (1995) 264-270
54. Hankinson S.E., London S.J., Chute C.G., et al. Effect of transport conditions on the stability of biochemical markers in blood. Clin Chem 35 12 (1989) 2313-2316
55. Lewis M.R., Callas P.W., Jenny N.S., et al. Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples. Thromb Haemost 86 6 (2001) 1495-1500
56. Chambless L.E., McMahon R., Finch A., et al. ARIC hemostasis study-III. Quality control. Atherosclerosis Risk in Communities. Thromb Haemost 70 4 (1993) 588-594
57. Fareed J., Baker W.H., Walenga J.M., et al. Molecular markers of hemostatic activation: future perspectives. Semin Thromb Hemost 10 4 (1984) 329-332
58. Amiral J., Adalbert B., and Adam M. Application of enzyme immunoassays to coagulation testing. Clin Chem 30 9 (1984) 1512-1516
59. Sambola A., Osende J., Hathcock J., et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 107 7 (2003) 973-977
60. Chomiki N., Henry M., Alessi M.C., et al. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost 72 1 (1994) 44-53
61. Declerck P.J., Alessi M.C., Verstreken M., et al. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 71 1 (1988) 220-225
62. Vaughan D.E. PAI-1 and atherothrombosis. J Thromb Haemost 3 8 (2005) 1879-1883
63. Declerck P.J., Moreau H., Jespersen J., et al. Multicenter evaluation of commercially available methods for the immunological determination of plasminogen activator inhibitor-1 (PAI-1). Thromb Haemost 70 5 (1993) 858-863
64. Fay W.P., Shapiro A.D., Shih J.L., et al. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 327 24 (1992) 1729-1733
65. Hersch S.L., Kunelis T., and Francis Jr. R.B. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor. Blood 69 5 (1987) 1315-1319
66. Lu H., Du Buit C., Soria J., et al. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy. Thromb Haemost 72 3 (1994) 438-443
67. Chandler W.L., Jascur M.L., and Henderson P.J. Measurement of different forms of tissue plasminogen activator in plasma. Clin Chem 46 1 (2000) 38-46
68. Morrissey J.H., Fakhrai H., and Edgington T.S. Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell 50 1 (1987) 129-135
69. Drake T.A., Morrissey J.H., and Edgington T.S. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 134 5 (1989) 1087-1097
70. Weiss H.J., Hoffmann T., Turitto V.T., et al. Further studies on the presence of functional tissue factor activity on the subendothelium of normal human and rabbit arteries. Thromb Res 73 5 (1994) 313-326
71. Edgington T.S., Mackman N., Brand K., et al. The structural biology of expression and function of tissue factor. Thromb Haemost 66 1 (1991) 67-79
72. Lindahl A.K. Tissue factor pathway inhibitor: from unknown coagulation inhibitor to major antithrombotic principle. Cardiovasc Res 33 2 (1997) 286-291
73. Stec J.J., Silbershatz H., Tofler G.H., et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 102 14 (2000) 1634-1638
74. Collet J.P., Montalescot G., Vicaut E., et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 108 4 (2003) 391-394
75. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 129 4 (1989) 687-702
76. Folsom A.R., Aleksic N., Park E., et al. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 21 4 (2001) 611-617
77. Smith A., Patterson C., Yarnell J., et al. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 112 20 (2005) 3080-3087
78. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 19 1 (1998) 61-109
79. Pradhan A.D., LaCroix A.Z., Langer R.D., et al. Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women. Circulation 110 3 (2004) 292-300
80. Shaper A.G., Pocock S.J., Walker M., et al. British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns. Br Med J (Clin Res Ed) 283 6285 (1981) 179-186
81. Lowe G.D., Danesh J., Lewington S., et al. Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 25 3 (2004) 252-259
82. Danesh J., Lewington S., Thompson S.G., et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294 14 (2005) 1799-1809
83. Steffel J., Luscher T.F., and Tanner F.C. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 113 5 (2006) 722-731
84. Soejima H., Ogawa H., Yasue H., et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 99 22 (1999) 2908-2913
85. Tutar E., Ozcan M., Kilickap M., et al. Elevated whole-blood tissue factor procoagulant activity as a marker of restenosis after percutaneous transluminal coronary angioplasty and stent implantation. Circulation 108 13 (2003) 1581-1584
86. Kim R.J., and Becker R.C. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 146 6 (2003) 948-957
87. Willeit J., and Kiechl S. Prevalence and risk factors of asymptomatic extracranial carotid artery atherosclerosis. A population-based study. Arterioscler Thromb 13 5 (1993) 661-668
88. Kiechl S., Muigg A., Santer P., et al. Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. Circulation 99 5 (1999) 614-619
89. Zahn R., Beeck H., Winkelmann B.R., et al. Prospective cross-sectional study of haemostatic factors in patients with and without coronary artery disease. Blood Coagul Fibrinolysis 13 2 (2002) 81-87
90. Gibbons R.J., Abrams J., Chatterjee K., et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 41 1 (2003) 159-168
91. Fuster V., Gotto A.M., Libby P., et al. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 1. Pathogenesis of coronary disease: the biologic role of risk factors. J Am Coll Cardiol 27 5 (1996) 964-976
92. Fareed J., Hoppensteadt D.A., Leya F., et al. Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. Clin Chem 44 8 Pt 2 (1998) 1845-1853
93. Corti R., and Badimon J.J. Value or desirability of hemorheological-hemostatic parameter changes as endpoints in blood lipid-regulating trials. Curr Opin Lipidol 12 6 (2001) 629-637